Drugmakers aren't spending as much on speaking fees these days. Some companies--namely Pfizer and Eli Lilly--have slashed physician payments by more than half.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Pfizer's once-gargantuan statin drug Lipitor has been cut down to size by generic competition. But if the drugmaker's plan to win over-the-counter status for the drug succeeds, Pfizer could add up to $1 billion back into its Lipitor franchise.
Is Pfizer and Bristol-Myers Squibb's Eliquis really safer than its competitors? A recent analysis of FDA adverse events reports suggested that it is.
Pfizer last year complicated a shortage of its hypothyroid drug Levoxyl when it tried a new manufacturing process. But manufacturing problems have been ironed out, and the company expects to have the drug back in consumers' hands by next week.
Pfizer is partnering with the Massachusetts Institute of Technology (MIT) to see if they can find new processes that will cut costs and increase efficiency, the Boston Business Journal reports.
Pfizer is one step closer to another $1 billion-plus in sales for its Prevnar 13 franchise. Data from a huge new study showed that Prevnar worked at preventing pneumonia in patients 65 or older, which puts the vaccine in line for stepped-up use.
The New York-based drugmaker is keeping the data under wraps until next month but has revealed the headline results. Primary and secondary objectives were all met.
Pfizer CEO Ian Read has become the first pharma executive to contribute an article to LinkedIn's publishing platform.
Since last August, when the Physician Payments Sunshine Act went into effect, drugmakers and devicemakers have been logging everything they've paid out to doctors. Now, it's finally time to report all those numbers to the Centers for Medicare & Medicaid Services.